REVENUE MEMORANDUM CIRCULAR NO. 19-2023 issued on February 6, 2023 publishes the January 4, 2023 letter from Food and Drug Administration Director General Samuel A. Zacate, endorsing updates to the “List of VAT-Exempt Medicines” under Republic Act No. 11534 (CREATE Act), which now includes certain medicines and medical devices for COVID-19 treatment.
               As clarified under Q&A No. 1 of Revenue Memorandum Circular No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall take effect on the date of publication by the FDA of the updates to the said list.